Filter Results
:
(173)
Show Results For
-
All HBS Web
(641)
- Faculty Publications (173)
Show Results For
-
All HBS Web
(641)
- Faculty Publications (173)
- December 2019
- Supplement
The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)
By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders.
In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or...
View Details
Keywords:
Opioids;
Addiction;
Business and Stakeholder Relations;
Product Launch;
Ethics;
Society;
Pharmaceutical Industry
Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)." Harvard Business School Supplement 720-423, December 2019.
- 2020
- Working Paper
How ESG Issues Become Financially Material to Corporations and Their Investors
By: George Serafeim
Management and disclosure of environmental, social and governance (ESG) issues have received substantial interest over the last decade. In this paper, we outline a framework of how ESG issues become financially material, affecting corporate profitability and valuation....
View Details
Keywords:
Materiality;
ESG;
Pharmaceutical Companies;
Business Ethics;
Sustainability;
Environment;
Disclosure;
Disclosure And Access;
Regulation;
Social Impact;
Environmental Sustainability;
Social Issues;
Corporate Governance;
Ethics;
Corporate Disclosure;
Corporate Accountability;
Resource Allocation;
Finance;
Accounting;
Valuation
Freiberg, David, Jean Rogers, and George Serafeim. "How ESG Issues Become Financially Material to Corporations and Their Investors." Harvard Business School Working Paper, No. 20-056, November 2019. (Revised November 2020.)
- October 2019
- Case
Impax Laboratories: Executing Accretive Acquisitions (A)
By: Benjamin C. Esty and Daniel Fisher
Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the...
View Details
Keywords:
Financial Reporting;
Financial Statements;
Mergers and Acquisitions;
Capital Structure;
Competition;
Competitive Advantage;
Corporate Strategy;
Pharmaceutical Industry;
United States
Esty, Benjamin C., and Daniel Fisher. "Impax Laboratories: Executing Accretive Acquisitions (A)." Harvard Business School Case 220-030, October 2019.
- October 2019
- Supplement
Impax Laboratories: Executing Accretive Transactions (A)
By: Benjamin C. Esty and Daniel Fisher
Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the...
View Details
- September 2019
- Case
Dementia Discovery Fund
By: Richard G. Hamermesh, Kathy Giusti and Sarah Gulick
The case is set in March 2019, and tells the story of the founding of the Dementia Discovery Fund (DDF). The idea for the fund began in 2015, when then-Prime Minister David Cameron spoke about the importance of making breakthroughs in dementia research, and pledged...
View Details
Keywords:
Venture Capital;
Investment Funds;
Mission and Purpose;
Recruitment;
Health Care and Treatment;
Pharmaceutical Industry;
Pharmaceutical Industry;
Boston;
Massachusetts;
London;
England
Hamermesh, Richard G., Kathy Giusti, and Sarah Gulick. "Dementia Discovery Fund." Harvard Business School Case 820-045, September 2019.
- 2019
- Article
Pay-for-Monopoly?: An Assessment of Reverse Payment Deals by Pharmaceutical Companies
By: Sana Rafiq and Max Bazerman
Abstract
Over the past eighteen years, pharmaceutical firms have developed a blueprint to impede competition in order
to maintain their monopoly profits. This scheme, termed pay-for-delay, involves direct or indirect payment of
money from a branded-drug manufacturer...
View Details
Rafiq, Sana, and Max Bazerman. "Pay-for-Monopoly? An Assessment of Reverse Payment Deals by Pharmaceutical Companies." Journal of Behavioral Economics for Policy 3, no. 1 (2019): 37–43.
- April 2019 (Revised April 2024)
- Case
Wendell Weeks at Corning Inc.: Extending a History of Life-Changing Innovations (A)
By: Ryan Raffaelli, David G. Fubini and Aldo Sesia
This case examines the leadership challenges associated with maintaining a culture of innovation in established organizations. It asks students to step into the shoes of a leader faced with making several tough decisions about when to invest (or to stop investing) in...
View Details
Keywords:
Innovation and Invention;
Organizational Culture;
Innovation Leadership;
History;
Technological Innovation;
Investment;
Decision Making
Raffaelli, Ryan, David G. Fubini, and Aldo Sesia. "Wendell Weeks at Corning Inc.: Extending a History of Life-Changing Innovations (A)." Harvard Business School Case 419-003, April 2019. (Revised April 2024.)
- April 2019 (Revised January 2022)
- Case
Clear Link Technologies, LLC: Driving Sales with Peer Effects
By: Christopher Stanton, Richard Saouma and Olivia Hull
The importance of a good peer or coworker is widely discussed, but understanding the glue that makes coworkers valuable is less understood. This case sheds light on the importance of peers and the practices and environments that make a group greater than the sum of its...
View Details
Keywords:
Talent and Talent Management;
Interactive Communication;
Experience and Expertise;
Decision Making;
Training;
Design;
Compensation and Benefits;
Knowledge Acquisition;
Knowledge Sharing;
Human Capital;
Working Conditions;
Measurement and Metrics;
Outcome or Result;
Performance;
Performance Improvement;
Research;
Sales;
Salesforce Management;
Motivation and Incentives;
Telecommunications Industry;
Utah;
United States
Stanton, Christopher, Richard Saouma, and Olivia Hull. "Clear Link Technologies, LLC: Driving Sales with Peer Effects." Harvard Business School Case 819-072, April 2019. (Revised January 2022.)
- December 2018
- Case
Corporate Transformation at Merck KGaA, Darmstadt, Germany
By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The...
View Details
Keywords:
Corporate Governance With Family Ownership;
Transformation;
Change Management;
Restructuring;
Corporate Governance;
Family Ownership
Fuller, Joseph B., Amy C. Edmondson, Daniela Beyersdorfer, and Tonia Labruyere. "Corporate Transformation at Merck KGaA, Darmstadt, Germany." Harvard Business School Case 319-072, December 2018.
- August 2018 (Revised February 2019)
- Case
Alvogen: Scaling Entrepreneurship
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Keywords:
Pharmaceutical Companies;
Scaling;
Generic Drugs;
Entrepreneurship;
Leadership;
Pharmaceutical Industry;
Asia;
Europe;
United States;
Iceland
Isenberg, Daniel, William R. Kerr, and Alexis Brownell. "Alvogen: Scaling Entrepreneurship." Harvard Business School Case 819-038, August 2018. (Revised February 2019.)
- February 2018 (Revised April 2018)
- Case
Yunnan Baiyao: Transforming a Chinese State-Owned Enterprise
By: Michael Chu, William C. Kirby, Nancy Hua Dai and Yuanzhuo Wang
This case tells the story of how Wang Minghui, Chairman of Yunnan Baiyao Group since 1999, transformed a single-product traditional Chinese medicine (TCM) state-owned enterprise (SOE) into a major diversified consumer health player in China's highly competitive...
View Details
Keywords:
State-owned Enterprise (SOE);
Traditional Chinese Medicine;
Yunnan;
Yunnan Baiyao;
Consumer Health;
Enterprise Transformation;
Transformation;
Health;
Business History;
State Ownership;
Private Ownership;
Business Strategy;
Commercialization;
Competition;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
China
Chu, Michael, William C. Kirby, Nancy Hua Dai, and Yuanzhuo Wang. "Yunnan Baiyao: Transforming a Chinese State-Owned Enterprise." Harvard Business School Case 318-078, February 2018. (Revised April 2018.)
- February 2018
- Case
Hikma Pharmaceuticals Governance Journey
By: Lynn Paine, Suraj Srinivasan and Gamze Yucaoglu
The case opens with Said Darwazah, chairman and CEO of Hikma Pharmaceuticals, the multinational generics company, anticipating the company’s 2017 AGM and reflecting on changes made over the previous year to address concerns expressed by proxy advisors and some...
View Details
Keywords:
Jordan;
Emerging Markets;
Private Sector;
For-profit Firms;
Boards Of Directors;
Pharmaceuticals;
Remuneration;
Shareholder Engagement;
Corporate Governance;
Governing and Advisory Boards;
Business and Shareholder Relations;
Executive Compensation;
Business Growth and Maturation;
Pharmaceutical Industry;
Jordan
Paine, Lynn, Suraj Srinivasan, and Gamze Yucaoglu. "Hikma Pharmaceuticals Governance Journey." Harvard Business School Case 318-108, February 2018.
- January 2018
- Supplement
BeiGene Supplemental PowerPoint
By: Willy C. Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window...
View Details
- December 2017
- Case
Charity or Bribery?
By: Eugene Soltes and Brian Tilley
Filip Kowalski, a senior manager at the pharmaceutical company Healthgen, leads sales for the firm’s Polish division. While pitching Healthgen’s products, he develops a relationship with a director of a regional health fund who also runs a private foundation. After a...
View Details
Keywords:
Bribery;
Crime and Corruption;
Law;
Ethics;
Philanthropy and Charitable Giving;
United States;
Europe
Soltes, Eugene, and Brian Tilley. "Charity or Bribery?" Harvard Business School Case 118-052, December 2017.
- December 2017 (Revised January 2018)
- Case
Alltech
By: David E. Bell and Natalie Kindred
Alltech was a Lexington, Kentucky–based producer of supplements for animal feed, with revenues of over $2 billion (projected to reach $3 billion in 2018), sales in 120 countries, 5,000 employees, and 100 manufacturing plants worldwide. For nearly four decades, Alltech...
View Details
Keywords:
Alltech;
United States;
Agribusiness;
Agriculture;
Animal;
Animal Agriculture;
Animal Feed;
Livestock;
Family Business;
Vertical Integration;
Strategy;
Growth;
Feed Additives;
Feed Supplements;
Kentucky;
Growth Strategy;
Family Businesses;
Animal-Based Agribusiness;
Acquisition;
Business Growth and Maturation;
Business Model;
Change Management;
Trends;
Governance;
Entrepreneurship;
Growth and Development;
Intellectual Property;
Leadership;
Management;
Markets;
Organizational Culture;
Private Ownership;
Science;
Quality;
Risk and Uncertainty;
Research;
Sales;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
Kentucky;
Brazil;
China
Bell, David E., and Natalie Kindred. "Alltech." Harvard Business School Case 518-001, December 2017. (Revised January 2018.)
- November 2017
- Case
BeiGene
By: Willy Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window...
View Details
Keywords:
Biotechnology;
Pharmaceutical Company;
Pharmaceuticals;
China;
Regulatory Environment;
Business Strategy;
Business Startups;
Innovation Strategy;
Situation or Environment;
Pharmaceutical Industry;
China
Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Case 618-033, November 2017.
- November 2017
- Case
The 'Wonder Drug' That Killed Babies
By: Joshua Lev Krieger, Tom Nicholas and Matthew Preble
In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children...
View Details
Keywords:
Regulation;
Business and Government Relations;
Business and Community Relations;
Business and Stakeholder Relations;
Product Marketing;
Corporate Social Responsibility and Impact;
Business History;
Health;
Government Legislation;
Corporate Accountability;
Ethics;
Governing Rules, Regulations, and Reforms;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
United Kingdom;
Australia;
Germany;
Europe
Krieger, Joshua Lev, Tom Nicholas, and Matthew Preble. "The 'Wonder Drug' That Killed Babies." Harvard Business School Case 818-044, November 2017.
- August 2017 (Revised July 2018)
- Case
MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work
By: Elie Ofek and Amanda Dai
In June 2014, MannKind Corporation announced that after years of development and billions of dollars in expenses, the FDA had finally approved its drug, Afrezza. MannKind would thus be the only company with an inhalable insulin on the market. As an alternative to...
View Details
Keywords:
Health Care and Treatment;
Product Launch;
Product Positioning;
Marketing Strategy;
Adoption;
Pharmaceutical Industry
Ofek, Elie, and Amanda Dai. "MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work." Harvard Business School Case 518-031, August 2017. (Revised July 2018.)
- June 2017
- Supplement
Transformation at Eli Lilly & Co. (B)
By: William R. Kerr and Alexis Brownell
Keywords:
Eli Lilly;
Pharmaceutical Companies;
Restructuring;
Organizational Change and Adaptation;
Pharmaceutical Industry;
Indiana;
Indianapolis
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (B)." Harvard Business School Supplement 817-136, June 2017.
- June 2017
- Supplement
Transformation at Eli Lilly & Co. (C)
By: William R. Kerr and Alexis Brownell
Keywords:
Eli Lilly;
Pharmaceutical Companies;
Restructuring;
Organizational Change and Adaptation;
Pharmaceutical Industry;
Indiana;
Indianapolis
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (C)." Harvard Business School Supplement 817-137, June 2017.